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Ageing, chronic conditions and the evolution of 
future drugs expenditures 
A five-year micro simulation from 2004 to 2029 
 
Thomas BARNAY (ERUDITE, Université Paris-Est Créteil – TEPP FR CNRS 3126) 
Sophie THIEBAUT (INSERM U912)1 
Bruno VENTELOU (INSERM U912 – CNRS Greqam/IDEP) 
Abstract 
 
• Context 
The healthy ageing assumptions may lead to substantial changes in paths of aggregate 
healthcare expenditures, notably catastrophic expenditures of people at the end of the life. But 
clear assessments of involved amounts are not available when we specifically consider 
ambulatory care (as drug expenditures) generally offered to chronically-ill people who can 
remain in this health-status for a long time onward. The Government and Social Security need 
tools to predict the future cost of health in particular drugs expenditures taking account 
epidemiological changes on future. This study estimates the evolution in reimbursable 
outpatient drug expenditures, attributable to age structure and chronic conditions changes, of 
the French population up to 2029. 
 
• Methods 
Matched data from both the 2004 Health and Social Protection Survey (carried out by IRDES) 
and from French Social Security databases were used in this study. We estimate the effects of 
epidemiological and life expectancy changes on French health expenditures until 2029 by 
applying a markovian microsimulation model from a nationally representative database. The 
originality of these simulations holds in using an aggregate indicator of morbidity-mortality, 
capturing vital risk and making it possible to adapt the quantification of life expectancies by 
taking into account the presence of severe chronic pathologies. Three epidemiological 
scenarios were constructed. 
 
• Findings 
We forecast future national drugs expenditures, under different epidemiological scenarios of 
chronic morbidity: Trend scenario, healthy ageing scenario and medical progress scenario. 
For the population aged 25+, results predict an increase in reimbursable drug expenditures of 
between 1.1% and 1.8% (annual growth rate), attributable solely to the ageing population and 
changes in health status. 
 
• Conclusion 
The small difference between the healthy ageing scenario (1.1%) and the simple continuation 
of trends scenario (1.4%) indicates that, contrary to expectations, reduced chronic conditions 
of future cohorts does not imply a large saving in terms of drug expenditures. 
 
Code JEL : C15, D12, I11 
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1 Introduction 
 
 
In 2009, health expenditures in France reached 11.5% of GDP and are likely to keep growing 
into the future. At the macro level, this trend is explained by five main factors: demography 
(Bebbington and  Shapiro, 2005), income effect2, innovation, the health care system 
characteristics (public/private insurance, public policy and organization scheme) and the price 
effect (see Dormont, Grignon et al., 2006 for a decomposition of these effects on past trends).  
 
In this paper, our attention is focused on the first factor and its future impact on drug 
expenditures. We propose an evaluation of the financial consequences of population age 
structure evolution (i.e.: proportion of old people in the population) and population size 
change, coupled with morbidity and mortality changes at the micro level. 
 
Drug expenditures are the main contributor of the growth in the volume of global health 
expenditures (increase in health expenditures in France saw an average annual growth rate of 
3.5% (in volume) from 2000 to 2008, while drug expenditures, during the same period, 
increased twice as quickly). Drug expenditures represented 20.5% of total health expenditures 
in 2008, or 544 Euros per inhabitant per annum, accounting for almost 2% of French GDP. 
Projections for drug expenditures therefore play a decisive role. The issues are industrial but 
also concern the financing of health expenditures, especially in the context of the recent 
growth seen in the use of generics together with the massive cut backs seen in drug 
reimbursements (in 2008, 65% of drug expenditures were reimbursed by the Social Security). 
 
In the past, demography had weak impact on the growth of health expenditures. From French 
data, Azizi and  Pereira, 2005 estimated that between 1970 and 1979 population ageing was 
annually responsible for 0.82% of spending growth with 0.65 points due to population 
increase and 0.17 points due to age structure changes. Dormont, Grignon et al., 2006 found, 
between 1992 and 2000, demographic changes were responsible for 7.63% or 0.92% 
annually. However the effects of demography will obviously be greater in the future with the 
baby-boomers reaching old age and the recent changes in longevity and health status. 
 
In France, life expectancy at age 60 is increasing on average by two months every year, and 
one third of the French population will be over 60 by 2030 (WHO, 2006). Moreover, it is 
commonly postulated that drug expenditures increases as a function of age. In this framework, 
population ageing is expected to result in large drug expenditures increases into the future. 
However, the explanatory power of age has been criticized by Zweifel, Felder et al., 1999, 
who consider this demographic concern a “red herring” argument. Age is not a stable 
explanatory variable for health expenditures, since morbidity and mortality are changing over 
time. Health status and “time to death” explain most of the expenditure, greatly mediating the 
impact of age (Yang, Norton et al., 2003; Stearns and  Norton, 2004; Shang and  Goldman, 
2008). Two possible scenarios are hypothesized to account for the observed increase in life 
expectancy and the likely impact on future health expenditures. First, medical and sanitary 
progress and healthier lifestyle choices have led to a longer healthy life expectancy 
(Olshansky and  Ault, 1986; Nusselder, 2002; Oeppen and  Vaupel, 2002).  Second, medicine 
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and treatment have led to an increase in life expectancy without increasing life quality by 
transforming deadly illnesses into chronic conditions (Michel and  Robine, 2004; Robine, 
2007). In that second case, chronic conditions become a highly relevant predictor of health 
expenditures during the life cycle at the micro-level, specifically regarding out-patient cares 
(Druss, Marcus et al., 2001; Fenina, Le Garrec et al., 2009). The micro-level nature of these 
important epidemiological transition variables (health status, time to death) strongly suggest 
that it is hazardous to rely on macro-level economic models to accurately determine future 
health expenditures. 
 
 
2 Methods 
 
Three steps are necessary to construct this micro-simulation: 
 
(i) The definition of representative cohorts using a database created from large samples 
representative of the national population.  
(ii) The artificial ageing of individuals, carried out using transition rates between health 
states. 
(iii) The estimation of the drug expenditures vector, and finally the “simulation” of 
these expenditures, which consists in applying the vector to the artificially aged 
population. 
2.1. Database 
The data used in this study come from the joint use of a database belonging to the principal 
French health insurance providers - entitled “Echantillon Permanent d’Assurés Sociaux 
(EPAS)” (i.e. Permanent Sample of Social Security Contributors), with a French household 
survey entitled “Enquête sur la Santé et la Protection Sociale (ESPS)” (i.e. Health, health care 
and insurance survey), carried out by the Institute of Research and Documentation in Health 
Economics (IRDES).  
 
EPAS comprises a panel of public health insurance recipients and contains exhaustive 
information about reimbursed expenditures by Social Security. The major advantage of this 
database is that it contains the exact values of out-patient expenditures, thereby avoiding any 
possible self reporting biases about healthcare consumptions. Note as well that the over-the-
counter medications are not recorded by this administrative file. On the other hand, the 
organization of health insurance payments within hospital structures is such that drug 
expenditures are not individually accounted for, but form part of a “collective expense” (a sort 
of public ownership). However in France, outpatient drug expenditures account for 82% of 
total drug expenditures reimbursed by the public health care system, and are therefore driving 
the growth of reimbursed drugs expenditures. 
 
The ESPS has been carried out using a self-administered survey every two years since 1988 in 
metropolitan France on a sample of 7,000 Social Security contributing households, or 22,000 
individuals which are representative of over 96% of the French population. This database 
contains a great deal of information about Social Security contributors: individual and 
household data, demographic and epidemiological characteristics (notably several summary 
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indicators of health status), socio-economic data, and information about individuals’ 
insurance coverage. 
 
In France, the ESPS coupled with the EPAS forms the only database cross-checking exact 
individual health expenditure with accurate information about insured. This database contains 
10,328 observations of which 6,996 were exploitable for this study. The data were adjusted 
using calibration on margins (for age, sex and for household income) in order to obtain a 
representative sample of the global metropolitan population of 62.4 million individuals. 
2.2 The chronic conditions measure 
Morbidity rates and healthy life expectancies, for a given cohort, change over time and 
modify the relationship between age, health status and health expenditures. As a result, age is 
not a stable determinant of health expenditures (Dormont, 2009).  
For example, Shang and Goldman, 2008 found a strong link between expenditures and 
self assessed health (SAH) after controlling for age. Indeed, age lost significance when SAH 
was introduced into the regression. The effects of age were thus explained by health status.   
.As well, the literature highlights that end of life expenditures explain the biggest part of the 
observed increase in expenditures associated with age, as the probability of dying is an 
increasing function of age (Zweifel, Felder et al., 1999; Yang, Norton et al., 2003; Stearns and  
Norton, 2004). Authors insist on the need to introduce a ‘time to death’ variable in the 
estimations, relating end-of-life expenditures with intensive care at hospital. In this paper we 
do not observe hospital spending but rather focus on another contributing factor than end of 
life: chronic illness and its potential compression, or expansion, within future cohort of older 
people (Stuckler, 2008). This variable of “chronic disease” better characterizes the (possibly 
long) life-history of people after 60 and is a better predictor of ambulatory expenditures, such 
as drugs. Thus, we need to determine a health status indicator which enables the evolution of 
chronic morbidity to be modeled, and more important, which gives us a consistent 
explanatory variable for the econometric model. 
 
Various instruments for measuring health status are available. We usually find three main 
dimensions in health measurement (Blaxter, 1989): lists of diseases and symptoms (medical 
model), activity limitations (functional model) and self-assessment health (SAH) measures 
(subjective model). To sidestep this difficulty IRDES researchers have built two health status 
indexes, vital risk and disability. These scores have been provided by doctors on the basis of 
ESPS database (Mizrahi and  Mizrahi, 1985). Vital risk corresponds to the death likelihood 
level and is built from illness and individual risk factors. It is rated on a 6-point scale from 
“no essential risk” to “a definite poor prognosis” which reflects an 80% probability of death 
within five years. Disability level induced by chronic conditions and is rated on an 8-point 
scale from “no impairment” to “permanently bed-ridden”. 
A chronic condition is one which medical treatment can alleviate but not cure. It is commonly 
described as a long-lasting or recurrent disease which generates disability. To capture those 
dimensions, we used the previous indexes to construct an aggregate binary index of health 
status by crossing the two variables3 of vital risk and disability, as described in appendix 
3.The proxy variable for chronic conditions is composed of two modes: healthy e1 and 
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 Note that the frontier has been chosen according to the classification made by Perronnin, M., L. Rochaix, et al. 
(2006). "Building a continuous indicator of state of health aggregating vital risk and disability (Construction 
d’un indicateur continu d’état de santé agrégeant risque vital et incapacité)." Questions d’Economie de la 
Santé(107). 
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unhealthy state e2. Thank to this synthetic indicator, it is not necessary to consider the whole 
range of diseases in order to predict future health expenditures. Furthermore, the problem of 
poly-diseases (i.e. co-morbidities), which are very frequent in those aged over-60, is 
immediately accounted for. The unhealthy state refers to serious pathologies or chronic 
diseases (e.g. diabetes) for which complete remission is not generally possible. Accordingly in 
the model, state e2 is semi-absorbent (i.e. it is not possible to pass from e2 to e1). 
 
2.3 The microsimulation model 
2.3.1 Artificial ageing of the database 
To simulate an individual’s future health status, we use an ageing algorithm based on 
Markov’s process (Briggs and  Sculpher, 1998). The artificial process of ageing needs the 
construction of transition rates matrices, which contain probabilities of transition from one 
health status to another. We consider a matrix constructed by age group (each age group being 
equal to 5 years) and by sex. We therefore identify 72 types of people (19 age groups + 2 
sexes + 2 health statuses; therefore 38 matrices containing 3 states of which 1 is an absorbing 
state - i.e. death) for which the pathway probabilities from one health status to another are 
different. At time t, an individual is either healthy or unhealthy. Then, at t+1 (i.e. five years 
later), health status will be determined by the probabilities of the transition matrix which 
he/she belongs to, knowing that his/her lottery (i.e. the line of the matrix) depends on his/her 
state of health at t. 
 
Therefore, the epidemiological dynamic is written as: 
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2.3.2 Construction of epidemiological scenarios 
In 2004, according to World Health Organization (WHO), the French spend on average 7.7 
years in poor health and can expect to remain in good health 90% of their lives (WHO, 2006). 
France is thus in a position of dynamic equilibrium (Manton, 1982; Robine and  Michel, 
2004) characterized by an increase in prevalence of chronic diseases, offset by a lower 
severity (Robine, Mormiche et al., 1996). We must therefore distinguish two epidemiological 
effects. On the one hand, the morbidity compression delaying the onset of disease in the life 
cycle and leads to longer life expectancy (Fries, 1980; Crimmins, 1990; Robine, 1992; Khaw, 
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1997; Nusselder, 2002). On the other hand, the expansion of morbidity is defined by 
extending the unhealthy life expectancy (Kramer, 1980; Fuchs, 1984). 
 
Population ageing is proposed according to three different scenarios of morbi-mortality. 
Except for the trend scenario, the previously calculated transition matrices are “deformed” in 
order to integrate epidemiological ageing hypotheses, basically by shifting transitions rate of 
the younger cohort to the older one. However, the shift is differentiated by sex. Meslé, 2004 
found accelerated growth in life expectancy and morbidity compression for males when 
compared to females, due to an increase in healthier behaviors on the part of men. Indeed in 
1990, the gap in life expectancy at birth was 8.2 years in 1990 and against men, it is in 2008 
equal to 6.7 years. 
 
Consequently we chose to differentiate between male and female morbidity (second and third 
scenario) and mortality (third scenario) evolution. To this end the shift is 10 years for men but 
only 5 for women. Thus men are catching up with women in terms of healthy life years and 
life expectancy.  
 
- Trend scenario 
Incidence and death rates are held constant with rates observed in 2004. The risk of falling ill 
is defined by reference to 2004, and we only take into account longer life span known as of 
2010. The matrices correspond therefore to current morbidity rates, which come directly from 
the cross-sectional analysis of the ESPS2004 database. Accordingly, after simulating the drug 
expenditures, we obtain the degree of increase in expenditures linked only to the demographic 
effects arising from the deformation of the age pyramid. The predicted expenditures within 
the framework of this scenario consequently are only the result of continuation of trends. 
 
 -“Healthy ageing” scenario 
This scenario is based on the hypothesis of reduced morbidity while mortality rates remain 
constant with the trend scenario. In order to obtain the healthy ageing scenario matrices, we 
reduce the probabilities of becoming chronically ill. Hence the probability of staying healthy 
is improved by the same magnitude as we do not change the death rates of the healthy 
population. 
This way reflects rejuvenation by a shift in biological age which is now distinct from 
chronological age - and therefore improves health status of future populations. From the shift 
in probabilities, we redefined the degree of longer life span through its redistribution between 
healthy and unhealthy days. This hypothesis translates Robine, 2007 theory on ageing and the 
rectangularization of the survival curve: longer life results from an improvement in health 
states. 
 
- Medical progress Scenario 
In this scenario, the healthy ageing hypothesis is kept. We add a hypothesis of reduced 
mortality for healthy and unhealthy people. Thus, we suppose that the future will bring a 
reduction in mortality rates of unhealthy (by the transformation of fatal pathologies into 
chronic ones). This is an extreme healthy ageing scenario, characterized by a complete 
rejuvenation of age groups, incorporating a longer life expectancy. This scenario corresponds 
to the modeling of medical-technical progress which, for unhealthy people (having passed 
into state 2), increases their life span. Here, “medical progress” is only defined in terms of its 
demographic and epidemiological impacts (e.g, no scenario for changes in prices is tested). 
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2.4 Estimation of drug expenditures 
2.4.1 The Econometric model 
In order to project drug expenditures, we have used an econometric model based on individual 
data. Generally, the econometric treatment of health expenditures requires particular 
characteristics to be taken into account, notably the presence of individuals who have had no 
consumption of drugs for a whole year. 
 
Although several estimation techniques are available, the analysis of the characteristics of the 
EPAS-ESPS2004 data determines the most suitable econometric model for drug expenditures. 
Twelve point five percent of the population had no drug expenditures in 2004. Based on 
Jones, 2000 and Deb and  Trivedi, 2006, the “two-part” model seems the most appropriate to 
deal with the problem of “zero expense”, as it separates consumption behavior into two steps. 
First, the individual decides whether to consume or not (part 1), and then he/she decides the 
degree of consumption based on different factors (part 2). The global model (i.e. the 
conditional mathematical expectation of expenditures) is obtained by multiplying the 
probability of the decision to consume by the estimated conditional expenditures: 
 
1, 2 1 2( / ) Pr( 0 / ) ( / , 0)p p p pi i i i i i iE y x y x E y x y= > >       (1) 
 
Where yi is the individual level of expenditures and 1, 2p pix is the vector of the expenditures 
explanatory co-variables (part 2) and of the decision to consume (part 1). The choice of such a 
modelization is also justified by the flexibility it brings to the model, by dividing the 
mechanism of consumption into nearly independent parts. The first part of the model (i.e. the 
probability of consuming), is estimated using a Logit: 
1
1 1
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p p
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e e
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        (2) 
Where 1 'pix β  is the expression of the predictions ( 1pix
 
the explanatory co-variables vector 
and β
 
the vector of parameters estimated from the Logit model) 
 
To model the second part of health expenditures we have the choice between two main types 
of models: generalized least squares models (GLM), and ordinary least squares (OLS) models 
with transformation of the dependent variable (see Manning and  Mullahly, 2001; Buntin and  
Zaslavsky, 2004 for an algorithm to determine the best data fitting method). Having tested 
both alternatives, the GLM was rejected due to flatness in the distribution of residuals 
(indicated by the kurtosis coefficient). An OLS log-transformed model, re-transformed using 
a smearing factor, was identified as the best fitting model for projections of drug expenditures 
based on EPAS-ESPS2004 (Duan, Manning et al., 1983). 
 
3 Results 
 
3.1 Econometric model predictions 
According to the methodological section, we proceed with the implementation of the two 
regression models, first in the general population and then in the consuming population. The 
result of these regressions is presented in appendices 2 and 3. Especially note that the health 
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status indicator is highly significant and captures well pharmaceutical expenditures 
heterogeneity in both parts of the model. Indeed, it appears to be the strongest expenditures 
predictor, while the impact of age remains very small.  “Chronic conditions” is indeed playing 
the same role for ambulatory expenditures as “time-to-death” in the inpatient expenditures 
case. 
 
Figure 1 enables the quality of predictions to be evaluated by establishing the comparison 
between the “real” expenditures (i.e. those coming from the database) and those which the 
model predicts for 2004. We then execute the model on the 2004 ESPS-EPAS survey data and 
simulate pharmacy based expenditures for 2004. The model respects the profile of 
expenditures very closely, in particular replicating the drop in expenditures after 80 years of 
age. 
 
Figure 1. Comparison of real expenditures with predicted expenditures 
 
 
3.2 Projected Populations and drug expenditures 
The simulations of different ageing scenarios for individuals enable the assessment of the 
effects of epidemiological changes on the demographic structure of the population to be 
carried out. Table 1 confirms the significant increase in the over 60 population, which 
practically doubles in size in the medical progress scenario. Moreover, this artificial ageing 
model is true to INSEE’s (National Institute of Statistics and Economic Studies) predictions,  
their trend scenario predicting 19.7 million people aged over 60 years by 2030 (Léon and  
Godefroy, 2006). However, the scenarios clearly differ in terms of the distribution of elderly 
people between the “sick” and “not-sick”. In 2004, 51% of the over-60 population was 
unhealthy.  
 
Whatever the scenario, the proportion of unhealthy people increases in the general population 
(+25). 27% of people aged 25 and over is in poor health in 2004. In 2029, this number reaches 
36% in the trend scenario, 29% in the healthy aging scenario and 33% in medical progress 
one. The examination of an older population increases the prevalence of the disease but only 
in the trend scenario and medical progress. In 2004, 51% of the population over 60 is 
unhealthy. In 2029 this proportion was 58% in the baseline scenario, 48% in the healthy aging 
scenario and 54% in that of medical progress. 
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Table 1: Population (in millions) in 2004 and 2029 according to 3 scenarios and distribution between the sick and 
people in good health 
 
ESPS 2004 Trend Scenario 
Healthy 
Ageing 
Scenario 
Medical 
Progress 
Scenario 
Population ≥ 25 42,62 49,38 49,93 53,46 
Whose healthy people 30,98 31,75 35,45 35,68 
Whose unhealthy people 11,65 17,63 14,47 17,77 
 ≥ 60 
Population ≥ 60 12,66 20,87 21,41 24,83 
Whose healthy people 6,16 8,84 11,21 11,44 
Whose unhealthy people 6,50 12,02 10,20 13,39 
 
Figure 2 shows the impact of the hypotheses of decreased morbidity (i.e. longer lifespan in 
good health) when underpinned by the healthy ageing and medical progress scenarios. 
Because in these two cases, the population is in better health than in the trend scenario, the 
average expenditures per age group are inferior. Mean expenditures in the medical progress 
scenario, which include a longer lifespan of both the sick and not-sick, are nevertheless higher 
than those for the healthy ageing scenario. In effect, in the former scenario, there is a greater 
number of unhealthy survivors. 
 
Figure 2. Average individual drug expenditures according to age and scenario 
 
 
Population ageing, even with healthy ageing, seems to be responsible for a significant 
increase in drug expenditures (Table 2). The simple effect of ageing in the French population 
should lead to an increase of 43% in drug expenditures for those over 25 years old (when 
compared with 2004 and the trend scenario). The healthy ageing hypothesis limits this 
increase only slightly as drug expenditures continue to grow substantially, increasing by 33%. 
The medical progress scenario predicts a much stronger increase. Expenditure from now until 
2029 could reach more than 35 billion Euros instead of the 22 billion Euros in 2004. 
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Table 2. Drug expenditures in 2004 and in 2029 according to the 3 scenarios and distribution between the healthy and 
unhealthy people (in billions euros) 
 
 
 
ESPS 2004 Trend Scenario 
Healthy 
Ageing 
Scenario 
Medical 
Progress 
Scenario 
Expenditures people ≥ 25 22,66 32,41 30,10 35,15 
Whose healthy people 8,25 9,19 10,81 10,92 
Whose unhealthy people 14,41 23,19 19,28 24,22 
  ≥ 60 
Expenditures people ≥ 60 12,40 23,87 22,15 27,14 
Whose healthy people 3,50 4,35 5,69 5,80 
Whose unhealthy people 8,90 19,48 16,46 21,34 
 
4 Discussion 
 
Longer life span is a matter of great debate amongst epidemiologists. In the future, shall it 
concern the compression of morbidity linked to an improvement in individual behaviours (e.g. 
improved daily hygiene and new knowledge in terms of preventive medicine (Fries, 1980; 
Crimmins, 1990; Robine, 1992; Nusselder, 2002) or instead shall it concern the development 
of medical progress and the nature of pathologies in elderly people, with a resulting automatic 
increase in the number of people living with chronic diseases Kramer, 1980; Fuchs, 1984? In 
the first case, the increase in life expectancy would be the result of increased life expectancy 
in good health, while, in the second case, life span while living with chronic disease would be 
prolonged. 
 
As economists, we take no position about these theses. Instead we provide the means to 
evaluate the consequences of both. We propose the scenarios reflecting these two alternatives, 
in order to evaluate their differential impact using the means of microsimulation. The 
originality of the study is also to use a health status variable indicating “chronic condition” 
which is appropriate for the prediction of ambulatory healthcare expenditures. Our results 
indicate that, despite the improvement of the health status of elderly and the large significance 
of the variable in elderly individual’s health consumptions, their expenditures are not 
considerably reduced in 2029, firstly because of a volume effect of elderly age-groups, who, 
from 2010 onwards, are particularly numerous in France. Moreover, unhealthy people drug 
expenditures go on growing with age, as the profile of expenditures does not depend solely on 
people’s health. Delaying the date of onset of chronic disease, the expenditures are not 
completely postponed. The healthy ageing scenario therefore would not be very “cost saving”, 
as it does not compensate for the predicted growth in the number of elderly people in France 
in 2029. 
 
Several hypotheses had to be carried out in order to make the technical treatment of this 
microsimulation possible. In our model, health status is summarized by a binary variable 
which does not take into account various levels of the seriousness of the state of the disease, 
nor the progressivity in the volume of medicine consumed by the sick, which is something 
that constitutes a limit of this tool. It does, however, involve the interaction between two 
different measurements of health state both diagnosed by medical professionals and 
consequently not self-declared. This important fact in turn limits individual heterogeneity 
biases. Moreover, the state of illness is seen as “absorbing”, that is to say that no remission is 
possible. Accordingly, this hypothesis, imposed by the complexity of the transition matrices, 
tends to overestimate the number of sick people and therefore the volume of medicines 
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consumed. We have tried to limit the consequences of this constraint by considering as “sick” 
all those persons who had a “very poor” life prognosis. 
 
The choice of scenarios can determine the nature of the results. We decided to consider that a 
global scenario of the expansion of morbidity did not appear a likely option. Obviously, it 
would appear necessary to follow the increase in the prevalence of diabetes and obesity, two 
illnesses which are likely to induce new drug expenditures. Besides, in order to construct the 
healthy ageing scenario, we decided to shift (back) men of two age brackets, with one age 
bracket for women. A greater degree of shift would obviously increase the effects of the 
scenario on expenditures. Nevertheless, we recognize that this assumption seems already 
relatively optimistic, and so we opted for a situation where the measured differences gave 
results which are a priori magnified. 
 
Despite these limits, rates of growth in drug expenditures seem relatively consistent with 
results from the literature. With regards to French data, two studies can be mentioned 
regarding total health expenditures (no estimations are available for drugs only). The OECD, 
2006 estimates that between 2005 and 2025 population ageing would annually account for 
+1.76% in the pessimistic assumption (increase of life expectancy trends are accounted for 
but the current age expenditures profile remains constant) and for +1.43% in the optimistic 
assumption (they propose a healthy ageing scenario in the sense that their expenditures age 
profile progressively shifts to the right). The European Comission and Economic Policy 
Commitee, 2006 estimate that between 2004 and 2030, demographic-related growth will 
annually account for +2.1% in the pessimistic assumption and +1.87% in the optimistic 
assumption. 
 
5 Conclusion 
 
To our knowledge, this work is the first prospective microsimulation model for determining 
drug expenditures in France by the year 2029. It allows considering the acceleration of the 
ageing population due to high fertility after the second world-war. Our results show the 
sensitivity of drug expenditures projections to demographic and epidemiological changes 
(including increase of chronic diseases of elderly). In addition to a baseline scenario, we 
decided to test a hypothesis of delayed age of disease (healthy ageing) and a scenario additive 
increases in life expectancy (medical progress).  
 
The pure effect of ageing of population in France is expected to generate an increase in drug 
spending of 43% (comparing 2004 and the trend scenario) equal to 1.44% of annual rate of 
growth). The assumption of healthy ageing is only slightly limiting growth. Drug spending 
continues to grow substantially, with a total increase of 33% (1.14 % of annual growth rate). 
The scenario anticipates medical advances grew significantly stronger. We notice that longer 
life span, notably for unhealthy people (i.e. the medical progress scenario), further accentuates 
the growth in drug expenditures associated with ageing. Drug expenditures by 2029 could 
reach more than 35 billion Euros against 22 in 2004 (1.77% of annual rate of growth).  
 
Of course, these evaluations constitute a ceteris paribus prediction in terms of the evolution of 
pharmaceutical expenditures in France – i.e. it only takes account of the “automatic” effect of 
ageing and changes in morbidity. These rates of growth in drug expenditures are the minimum 
rates. 
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The drugs regulation policy of the French health care system could also play an important role 
in the future of reimbursed drugs expenditures. First, the authorization for the drug market is 
highly regulated. Reimbursed Drug Prices (and reimbursement rate) are not Market Prices but 
negotiated between the relevant public authorities and the pharmaceutical industries. Drug 
Volumes partially depend on Parliament regulation. Any change in this policy (e.g. a decrease 
of reimbursement rate) can modify the dynamics of drug expenditures, in value and perhaps in 
volume. 
 
Other factors will play a role as follows: therapeutic decisions favoring the use of medicines 
(e.g. substituting surgery or other therapeutic actions for medicines, or innovations in 
available molecules); modification of relative prices; intensification of the demand for 
healthcare (cultural reasons). Healthcare seeking behaviors are also dictated both by the level 
of drug expenditures reimbursement and the level of coverage provided by complementary 
health insurance. 
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Appendix 1. Transitions states 
 
Table 3: Example of transition rates for female aged 50 to 59 years old 
Female P(e1->e1) P(e1->e2) P(e1->e3) P(e2->e2) P(e2->e3) 
Trend 
50-54  0,9102 0,0825 0,0072 0,9781 0,0218 
55-59 0,8908 0,1001 0,0091 0,9723 0,0277 
      
HA 
50-54  0,9266 0,0661 0,0072 0,9781 0,0218 
55-59  0,9102 0,0805 0,0091 0,9723 0,0277 
      
MP 
50-54  0,9266 0,0681 0,0052 0,9843 0,0157 
55-59  0,9102 0,0825 0,0072 0,9781 0,0218 
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Appendix 2. Descriptive Statistics 
 
Table 4. Co-variable descriptive statistics 
Variable Modality Distribution (%) 
 
Sex 
 
Men 
 
47.15 
 
Women 52.85 
 
  
Health state Indicator In good health 72,67 
 
Chronic Disease 27,33 
 
  
Complementary Health Insurance Has Com Health Ins 88.01 
 
Does not have Comp Health Ins 11.99 
 
  
CMU* ( Special Public 
Complementary Insurance) 
CMU recipients 4.25 
 
Not a recipient of CMU 95.75 
  
 
Body Mass Index (BMI) Underweight 2.80 
 
Overweight 31.54 
 
Obese 12.54 
 
Normal 53.11 
 
  
(Public) Health Insurance Regime Special Regime 24.28 
 
General Regime 75.72 
 
  
Alcohol Profile Non drinker 24.04 
 
Not at-risk drinker 48.55 
 
At risk drinker 27.41 
 
  
Tobacco Smoker 23.81 
 
Non smoker 76.19 
 
  
Doctor Density High Doctor density 50.60 
 
Low doctor density 49.40 
  
 
Couples Not living in a couple 22.11 
 
Living in a couple 77.89 
  
* CMU is a public supplementary health insurance program which grants free of charge to 
those households with an annual income of around 9,000 Euros or less.
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Appendix 3. Building the binary chronic conditions variable 
 
To build the health status indicator we cross the vital risk and the disability variable as follow : 
 
Table 5. Binary Chronic conditions status 
 
    
Disability Index 
  
 
0 1 2 3 4 5 6 7 
0 
1   
2 
Healthy Status 
3 
4 
V
ita
l R
isk
 
In
de
x
 
5   
Unhealthy status 
 
 
Table 6. Items of the Disability Index 
0 No Disability 
1 Minimal Disability 
2 Few Disability 
3 Disability, but Normal Living 
4 Have to Decrease Professional and Household Activities 
5 Low Autonomy 
6 No Household Autonomy  
7 Full time Confinement to Bed 
 
 
Table 7. Items of the Vital Risk Index 
0 No Vital Risk 
1 Very Low Poor Prognosis 
2 Low Poor Prognosis  
3 Possible Vital Risk 
4 Poor Prognosis 
5 Very Poor Prognosis 
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Appendix 4. Estimation of the probability of being a consumer of reimbursed medicines 
 
 
Table 8. Association of predicted probabilities and observed responses 
Concordant Percentage 73.6 Somers' D 0.477 
Discordant Precentage 25.9 Gamma 0.480 
Ties percentage 0.5 Tau-a 0.106 
Pairs 1627968 c 0.739 
 
Table 9. The logistic model: the probability of being a consumer of reimbursed medicines 
Odds Ratios 
Effect Estimated 
Point 
95% Wald Confidence 
Interval 
Has a Chronic disease  2.785 1.975 3.928 
Age 1.007 0.780 1.300 
Age2 0.999 0.994 1.004 
Age3 1.000014 1.000 1.000 
Has complementary Health insurance  2.571 1.822 3.627 
CMU recipients 4.674 1.926 11.343 
General Insurance regime vs Special Insurance Regime 1.712 1.308 2.240 
Living in a couple 1.366 1.038 1.798 
Women  2.026 1.563 2.628 
 
   
High Doctor Density VS Low Doctor density 1.292 1.049 1.592 
Y = 1 represents 12.48% of the weighted sample of those over 25 years old 
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Appendix 5. Estimation of expenditures for reimbursed medicines 
 
Table 10. Statistics of OLS model 
R-square 0.3926 
Root mean square of error 1.2366 
Degrees of freedom 3335 
 
Table 11. Estimated coefficients of regression 
Parameter Estimation Standard error t Test value Pr > |t| 
Constant 6.1433204 0.78592090 7.82 <.0001 
Has a Chronic Disease 1.0814673 0.05681064 19.04 <.0001 
Age -0.1994922 0.04617721 -4.32 <.0001 
Age2 0.0043394 0.00086101 5.04 <.0001 
Age3 -0.0000253 0.00000494 -5.12 <.0001 
Health Insurance 0.3402625 0.08741645 3.89 0.0001 
CMU recipients 0.5041919 0.18191389 2.77 0.0056 
Body Mass Index (BMI) Normal Reference 
BMI Underweight 0.3997516 0.16217829 2.46 0.0138 
BMI Overweight 0.1619703 0.05054641 3.20 0.0014 
BMI Obese 0.3142043 0.07027668 4.47 <.0001 
Alcohol profile : at risk Consumer Reference 
Alcohol profile : non Consumer 0.4052201 0.07552941 5.37 <.0001 
Alcohol profile : not at risk Consumer 0.1887194 0.06445822 2.93 0.0034 
Women 0.2753358 0.05587362 4.93 <.0001 
Non-smoker 0.1615484 0.06053003 2.67 0.0076 
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